Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?

× No keyword cloud information.

9 in total

Review 1. The GIST paradigm: lessons for other kinase-driven cancers.

Authors: Cristina R Antonescu
Journal: J Pathol Date: 2010-10-26 Impact factor: 7.996

2. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.

Authors: Yong-Wan Kim; Ta Jen Liu; Dimpy Koul; Ningyi Tiao; Abdullah H Feroze; Jing Wang; Garth Powis; W K Alfred Yung
Journal: Neuro Oncol Date: 2011-04 Impact factor: 12.300

3. Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

Authors: M Preusser; E Gelpi; A Rottenfusser; K Dieckmann; G Widhalm; W Dietrich; A Bertalanffy; D Prayer; J A Hainfellner; Christine Marosi
Journal: J Neurooncol Date: 2008-05-06 Impact factor: 4.130

4. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.

Authors: Toshimasa Akazawa; Shawn G Kwatra; Laura E Goldsmith; Mark D Richardson; Elizabeth A Cox; John H Sampson; Madan M Kwatra
Journal: J Neurochem Date: 2009-03-11 Impact factor: 5.372

5. Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.

Authors: Nidhi Bansal; Jade Mims; Jeffrey G Kuremsky; Amy L Olex; Weiling Zhao; Leimiao Yin; Revati Wani; Jiang Qian; Brian Center; Glen S Marrs; Mercedes Porosnicu; Jacquelyn S Fetrow; Allen W Tsang; Cristina M Furdui
Journal: Antioxid Redox Signal Date: 2014-04-10 Impact factor: 8.401

9. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.

Authors: Qiang Huang; Quan-Bin Zhang; Jun Dong; Yin-Yan Wu; Yun-Tian Shen; Yao-Dong Zhao; Yu-De Zhu; Yi Diao; Ai-Dong Wang; Qing Lan
Journal: BMC Cancer Date: 2008-10-22 Impact factor: 4.430

9 in total

Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?

Review 1. The GIST paradigm: lessons for other kinase-driven cancers.

2. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.

3. Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

4. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.

5. Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.

Review 6. Correlative studies in neuro-oncology trials: should they influence treatment?

7. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Review 8. When orthologs diverge between human and mouse.

9. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.